Anticoagulation strategies for treatment of ischemic stroke and antiphospholipid syndrome: Case report and review of the literature

Pharmacotherapy

Volumn 26, Issue 10, 2006, Pages 1518-1525

  Patterson, Shawnna L ^a   LaMonte, Marian P ^a   Mikdashi, Jamal A ^a   Haines, Stuart T ^a,b   Hursting, Marcie J ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c Clinical Science Consulting   (United States)

Author keywords

Anticoagulation; Antiphospholipid syndrome; Argatroban; Fondaparinux; Heparin induced thrombocytopenia; HIT; Ischemic stroke; Thrombosis; Warfarin induced necrosis

Indexed keywords

ARGATROBAN; AZATHIOPRINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; DEXAMETHASONE; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; HYDROXYCHLOROQUINE; LEPIRUDIN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ADULT; ANAPHYLAXIS; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; BLEEDING; BRAIN INFARCTION; CASE REPORT; CAUCASIAN; CEREBROVASCULAR ACCIDENT; DEBRIDEMENT; DRUG MECHANISM; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNOMODULATION; LIVER TOXICITY; MALE; NEUROLOGIC DISEASE; REVIEW; SKIN NECROSIS; THROMBOSIS;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; AZATHIOPRINE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DEXAMETHASONE; HUMANS; MALE; MIDDLE AGED; PIPECOLIC ACIDS; STROKE; WARFARIN;

EID: 33749487845     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.10.1518     Document Type: Review

References (38)

1. Adams HP Jr, Adams RJ, Brott T, et al. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the stroke council of the American Stroke Association. Stroke 2003;34:1056-83.
2. Al-Sadat A, Sunbulli M, Chaturvedi S. Use of intravenous heparin by North American neurologists: do the data matter? Stroke 2002;33:1574-7.
3. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 2004;164:361-9.
4. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126;311-37S.
5. Lewis BE, Wallis DE, Leya F, Bursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003;163:1849-56.
6. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-43.
7. Lewis BE, Matthai WH, Cohen M, Moses JW, Hursting MJ, Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cathet Cardiovasc Intervent 2002;57:177-84.
8. LaMonte MP, Nash ML, Wang DZ, et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke 2004;35:1677-82.
9. LaMonte MP, Brown PM, Hursting MJ. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit Care Med 2004;32:976-80.
10. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999;99:73-80.
11. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999;100:587-93.
12. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003;108:2062-5.
13. Harrigan MR, Levy EI, Bendok BR, Hopkins LN. Bivalirudin for endovascular intervention in acute ischemic stroke: case report. Neurosurgery 2004;54:218-23.
14. Anonymous. Physicians' desk reference, 54th ed. Montvale, NJ: Medical Economics Company, Inc, 2000:969-74.
15. Chan YC, Valenti D, Mansfield D, Stansby G. Warfarin induced skin necrosis. Br J Surg 2000;87:266-72.
16. Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russell JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997;127:804-12.
17. Toubi E, Kessel A, Shoenfeld Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol 2005;66:395-402.
18. Lavalle-Graef A, Villegas-Acosta L, Lavalle C. Trends of anticardiolipin antibodies after low-dose methylprednisolone and cyclophosphamide treatment of systemic lupus erythematosus. Arch Med Res 2004;35:421-7.
19. Asherson RA. Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome. Immunobiology 2005;210:727-33.
20. Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004;291:576-84.
21. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-51.
22. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with antiphospholipid antibody syndrome. N Engl J Med 2003;349:1133-8.
23. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997;127:177-85.
24. Mant MJ, Stang L, Etches WS. Warfarin monitoring in patients with anticardiolipin antibodies, but without lupus anticoagulants. Thromb Res 2000;99:477-82.
25. Yamazaki M, Asakura H, Saito M, et al. Prothrombin fragment 1+2 measures treatment effect in patients with antiphospholipid syndrome. Thromb Res 1998;91:121-8.
26. Schulman S, Wahlander K, Lundstrom T, Clason SB, Ericksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-20.
27. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349:1695-702.
28. Savi P, Chong BH, Greinacher A, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005;105:139-44.
29. Harenberg J, Jörg I, Fenyvesi T. Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica 2004;89:1017-18.
30. Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost 2005;93:999-1000.
31. Hassell K. The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapy Chest 2005;127(suppl 2):1-8S.
32. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins lupus cohort perspective. Scand J Rheumatol 1996;25:191-3.
33. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology 2002;41:924-9.
34. Johnson R, Charnley J. Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty. Clin Orthop Relat Res 1979;144:174-7.
35. Asherson RA. The catastrophic antiphospholipid syndrome, 1998; a review of the clinical features, possible pathogenesis and treatment. Lupus 1998;7(suppl 2):S55-62.
36. Statkute L, Traynor A, Oyama Y, et al. Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation. Blood 2005;106:2700-9.
37. Roubey R. New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. Arthritis Rheum 2003;48:3004-8.
38. Cockerill KA, Iverson GM, Jones DS, Linnik MD. Therapeutic potential of toleragens in the management of antiphospholipid syndrome. BioDrugs 2004;18:297-305.